1nhaler Ltd

1nhaler develops a proprietary single-dose dry powder inhaler using unique membrane technology, designed to be the world's smallest, simplest, and most sustainable inhaler made predominantly from cardboard. It targets respiratory and inhalable drug delivery with a low-cost, low-carbon footprint device the size of a credit card.

  • Early Stage
  • Healthtech
  • Medical Devices
  • Sustainability
  • Healthcare & Life Sciences

1

Round

1

Industry

4

Tags

Nov 3, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 3, 2026

    GBP 2.2M

    Seed

    Led by Archangel Investors

    • Scottish Enterprise
    • Archangel Investors
    • British Business Bank

    Article coming soon.

Pricing

Research 1nhaler Ltd — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if 1nhaler Ltd is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational